Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

BACKGROUND/AIM: Lysozyme (mucopeptide N-acetyl-muramyl hydrolase) is widely used as a mucolytic and anti-inflammatory agent in Japan. We evaluated the effects of long-term lysozyme administration on COPD exacerbation. METHODS: In a 1-year, randomized, double-blind, placebo-controlled, parallel trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuchi, Yoshinosuke, Tatsumi, Koichiro, Inoue, Hiromasa, Sakata, Yukinori, Shibata, Kai, Miyagishi, Hideaki, Marukawa, Yasuhiro, Ichinose, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846053/
https://www.ncbi.nlm.nih.gov/pubmed/27143873
http://dx.doi.org/10.2147/COPD.S103105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846053/
https://www.ncbi.nlm.nih.gov/pubmed/27143873
http://dx.doi.org/10.2147/COPD.S103105

Ejemplares similares